Sergio Traversa - 09 Sep 2024 Form 4 Insider Report for RELMADA THERAPEUTICS, INC. (RLMD)

Role
Chief Executive Officer, Director
Signature
/s/ Sergio Traversa
Issuer symbol
RLMD
Transactions as of
09 Sep 2024
Net transactions value
+$395,115
Form type
4
Filing time
11 Sep 2024, 17:47:15 UTC
Previous filing
29 May 2024
Next filing
20 May 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLMD Common Stock Purchase $150,619 +55,579 +23% $2.71 299,603 09 Sep 2024 Direct F1, F2
transaction RLMD Common Stock Purchase $90,788 +33,014 +11% $2.75 332,617 10 Sep 2024 Direct F1, F3
transaction RLMD Common Stock Purchase $153,707 +51,407 +15% $2.99 384,024 11 Sep 2024 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
F2 Purchase prices range from $2.51 to $2.85 per share, inclusive.
F3 Purchase prices range from $2.73 to $2.80 per share, inclusive.
F4 Purchase prices range from $2.84 to $3.05 per share, inclusive.